Relmada Therapeutics Net Worth
Relmada Therapeutics Net Worth Breakdown | RLMD |
Relmada Therapeutics Net Worth Analysis
Relmada Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Relmada Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Relmada Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Relmada Therapeutics' net worth analysis. One common approach is to calculate Relmada Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Relmada Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Relmada Therapeutics' net worth. This approach calculates the present value of Relmada Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Relmada Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Relmada Therapeutics' net worth. This involves comparing Relmada Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Relmada Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Relmada Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Relmada Therapeutics' net worth research are outlined below:
| Relmada Therapeutics had very high historical volatility over the last 90 days | |
| Relmada Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (98.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Relmada Therapeutics currently holds about 211.96 M in cash with (51.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Relmada Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Relmada Therapeutics to Present at Jefferies London Healthcare Conference |
Relmada Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Relmada Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Relmada Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Relmada Therapeutics Target Price Consensus
Relmada target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Relmada Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 4 | Strong Buy |
Most Relmada analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Relmada stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Relmada Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationRelmada Therapeutics Target Price Projection
Relmada Therapeutics' current and average target prices are 3.02 and 10.38, respectively. The current price of Relmada Therapeutics is the price at which Relmada Therapeutics is currently trading. On the other hand, Relmada Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Relmada Therapeutics Market Quote on 1st of December 2024
Target Price
Analyst Consensus On Relmada Therapeutics Target Price
Know Relmada Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Relmada Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Relmada Therapeutics backward and forwards among themselves. Relmada Therapeutics' institutional investor refers to the entity that pools money to purchase Relmada Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Deutsche Bank Ag | 2024-06-30 | 224.8 K | Bank Of America Corp | 2024-06-30 | 208 K | Two Sigma Investments Llc | 2024-09-30 | 191.3 K | Bridgeway Capital Management, Llc | 2024-09-30 | 181.1 K | Rbf Llc | 2024-06-30 | 165.5 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 157.7 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 156.6 K | Group One Trading, Lp | 2024-06-30 | 148.9 K | Barclays Plc | 2024-06-30 | 146 K | Franklin Resources Inc | 2024-09-30 | 1.3 M | Vanguard Group Inc | 2024-09-30 | 1.3 M |
Follow Relmada Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 91.13 M.Market Cap |
|
Project Relmada Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.01) | (1.06) | |
| Return On Capital Employed | (1.21) | (1.28) | |
| Return On Assets | (1.01) | (1.06) | |
| Return On Equity | (1.16) | (1.22) |
When accessing Relmada Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Relmada Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Relmada Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Relmada Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Relmada Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Relmada Therapeutics' management manipulating its earnings.
Evaluate Relmada Therapeutics' management efficiency
Relmada Therapeutics has return on total asset (ROA) of (0.5913) % which means that it has lost $0.5913 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0041) %, meaning that it created substantial loss on money invested by shareholders. Relmada Therapeutics' management efficiency ratios could be used to measure how well Relmada Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2024, Return On Tangible Assets is expected to decline to -1.06. In addition to that, Return On Capital Employed is expected to decline to -1.28. At present, Relmada Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Asset Turnover is expected to grow to 0.52, whereas Total Current Assets are forecasted to decline to about 60.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.84 | 2.93 | |
| Tangible Book Value Per Share | 2.84 | 2.93 | |
| Enterprise Value Over EBITDA | 24.54 | 25.77 | |
| Price Book Value Ratio | 1.46 | 1.39 | |
| Enterprise Value Multiple | 24.54 | 25.77 | |
| Price Fair Value | 1.46 | 1.39 | |
| Enterprise Value | 120.5 M | 108.7 M |
Relmada Therapeutics has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Return On Equity (1.00) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Relmada Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Relmada Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Relmada Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Relmada Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 23rd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 30th of August 2024 Other Reports | ViewVerify |
Relmada Therapeutics Earnings per Share Projection vs Actual
Relmada Therapeutics Corporate Management
| John Hixon | Head Commercial | Profile | |
| Marco MD | Chief Officer | Profile | |
| Andrew Cutler | Senior Advisor | Profile | |
| Richard Mangano | Chief Scientific Officer | Profile | |
| MBA MBA | CEO Director | Profile | |
| RPh MBA | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relmada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Relmada Therapeutics. If investors know Relmada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Relmada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.86) | Return On Assets (0.59) | Return On Equity (1.00) |
The market value of Relmada Therapeutics is measured differently than its book value, which is the value of Relmada that is recorded on the company's balance sheet. Investors also form their own opinion of Relmada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Relmada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Relmada Therapeutics' market value can be influenced by many factors that don't directly affect Relmada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Relmada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Relmada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Relmada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.